CombiMatrix Gains Conditional NYS Approval for Pediatric Disorders Array Test | GenomeWeb

NEW YORK (GenomeWeb) – CombiMatrix announced today that it has received conditional approval from the New York State Department of Health to market its CombiSNP chromosomal microarray analysis test for pediatric development disorders.

By gaining conditional approval, CombiMatrix will be able to market the test in New York while the assay is under Clinical Laboratory Reference System review. Upon completion of the review, either the test will receive full approval or additional information will be required in order to achieve final approval, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.